TCS bags $1.5-bn contract from US drug firm Walgreens Boots Alliance

The expansion of WBA and TCS strategic partnership is based on WBA's review of its IT operating model and vendor landscape

The company already enjoys a 67-68 per cent share of the respiratory drugs market in India and has potential for a 14-15 per cent growth
Press Trust of India New Delhi
2 min read Last Updated : Feb 03 2020 | 10:25 PM IST

IT major Tata Consultancy Services on Monday said it has bagged a $1.5 billion (about Rs 10,650 crore) contract from pharma company Walgreens Boots Alliance, spread over a period of 10 years.

Under the contract, TCS will provide managed services including application maintenance and support, required infrastructure and security operations.

"Tata Consultancy Services has expanded its long-standing partnership with Walgreens Boots Alliance, a global leader in retail and wholesale pharmacy, to transform the latter's IT operating model. The contract is valued at over $1.5 billion over a ten-year period," TCS said in a BSE filing.

The expansion of WBA and TCS strategic partnership is based on WBA's review of its IT operating model and vendor landscape.

As a result, the WBA global IT team will focus on leading and supporting strategic technology projects that create customer value through the development of new digital products and services on its business platforms.

"The TCS strategic partnership will enhance our ability to rapidly address evolving business needs, support large-scale global technology solutions and promote investment in truly differentiating capabilities through a modernized platform," WBA Senior Vice President and Global Chief Information Officer Francesco Tinto said in a statement.

The TCS approach will blend artificial intelligence, machine learning and advanced software engineering to enhance operational resilience and boost productivity, the statement said.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :TCSpharma firmsPharma sector

First Published: Feb 03 2020 | 9:45 PM IST

Next Story